PDF下载 ( 1884 KB)
Research advances in the pathogenesis of nonalcoholic fatty liver disease-related hepatocellular carcinoma
-
摘要:
非酒精性脂肪性肝炎/非酒精性脂肪性肝病（NASH/NAFLD）已经逐渐发展成为西方发达国家肝细胞癌（HCC）的主要病因之一。不同于经典的肝炎-肝硬化-肝癌疾病演变过程,近40%的NAFLD相关HCC可不经历肝硬化直接进展为HCC,表明其可能有不同的发病机制。阐述了关于NAFLD相关HCC发病机制的最新研究进展。
Abstract:Nonalcoholic steatohepatitis( NASH)/nonalcoholic fatty liver disease( NAFLD) has gradually become one of the main causes of hepatocellular carcinoma( HCC) in Western developed countries. Different from the typical evolution process of hepatitis,liver cirrhosis,and liver cancer,nearly 40% NAFLD patients can progress into HCC without experiencing liver cirrhosis,suggesting other mechanisms may play a role in this process. This article elaborates on the latest research advances in the pathogenesis of NAFLD-related HCC.
-
[1] ANSTEE QM,REEVES HL,KOTSILITI E,et al. From NASH to HCC:Current concepts and future challenges[J]. Nat Rev Gastroenterol Hepatol,2019,16(7):411-428. [2] LEUNG C,YEOH SW,PATRICK D,et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic nonalcoholic fatty liver disease[J]. World J Gastroenterol,2015,21(4):1189-1196. [3] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J]. Hepatology,2016,64(1):73-84. [4] KAWAMURA Y,ARASE Y,IKEDA K,et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma[J]. Am J Gastroenterol,2012,107(2):253-261. [5] BENGTSSON B,STL P,WAHLIN S,et al. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis[J]. Liver Int,2019,39(6):1098-1108. [6] LIU Y,LIU L,ZHOU Y,et al. CKLF1 enhances inflammationmediated carcinogenesis and prevents doxorubicin-induced apoptosis via IL6/STAT3 signaling in HCC[J]. Clin Cancer Res,2019,25(13):4141-4154. [7] SHARMA D,WANG J,FU PP,et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis[J]. Hepatology,2010,52(5):1713-1722. [8] DALAMAGA M,DIAKOPOULOS KN,MANTZOROS CS. The role of adiponectin in cancer:A review of current evidence[J]. Endocr Rev,2012,33(4):547-594. [9] HILL-BASKIN AE,MARKIEWSKI MM,BUCHNER DA,et al.Diet-induced hepatocellular carcinoma in genetically predisposed mice[J]. Hum Mol Genet,2009,18(16):2975-2988. [10] SHEN J,TSOI H,LIANG Q,et al. Oncogenic mutations and dysregulated pathways in obesity-associated hepatocellular carcinoma[J]. Oncogene,2016,35(49):6271-6280. [11] LUO Y,TIAN G,ZHUANG Z,et al. Berberine prevents nonalcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice[J]. Am J Transl Res,2019,11(5):2668-2682. [12] GRETEN TF,EGGERT T. Cellular senescence associated immune responses in liver cancer[J]. Hepat Oncol,2017,4(4):123-127. [13] HIGHFILL SL,CUI Y,GILES AJ,et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy[J]. Sci Transl Med,2014,6(237):237ra67. [14] TAVAZOIE MF,POLLACK I,TANQUECO R,et al. LXR/ApoE activation restricts innate immune suppression in cancer[J].Cell,2018,172(4):825-840. e18. [15] ZHENG J,CAI J,LI H,et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments:A Meta-analysis and systematic review[J]. Cell Physiol Biochem,2017,44(3):967-981. [16] van der WINDT DJ,SUD V,ZHANG H,et al. Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis[J].Hepatology,2018,68(4):1347-1360. [17] BIJNEN M,JOSEFS T,CUIJPERS I,et al. Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice[J]. Gut,2018,67(7):1317-1327. [18] YE D,YANG K,ZANG S,et al. Lipocalin-2 mediates nonalcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2[J]. J Hepatol,2016,65(5):988-997. [19] CHEN J,LIANG B,BIAN D,et al. Knockout of neutrophil elastase protects against western diet induced nonalcoholic steatohepatitis in mice by regulating hepatic ceramides metabolism[J]. Biochem Biophys Res Commun,2019,518(4):691-697. [20] PUIG T,TURRADO C,BENHAMU'B,et al. Novel inhibitors of fatty acid synthase with anticancer activity[J]. Clin Cancer Res,2009,15(24):7608-7615. [21] BELORIBI-DJEFAFLIA S,VASSEUR S,GUILLAUMOND F.Lipid metabolic reprogramming in cancer cells[J]. Oncogenesis,2016,5:e189. [22] IWAMOTO H,ABE M,YANG Y,et al. Cancer lipid metabolism confers antiangiogenic drug resistance[J]. Cell Metab,2018,28(1):104-117. e5. [23] JHO D,BABCOCK TA,HELTON WS,et al. Omega-3 fatty acids:Implications for the treatment of tumor-associated inflammation[J]. Am Surg,2003,69(1):32-36. [24] LU X,ZHANG X,ZHANG Y,et al. Metabolic profiling analysis upon acylcarnitines in tissues of hepatocellular carcinoma revealed the inhibited carnitine shuttle system caused by the downregulated carnitine palmitoyltransferase 2[J]. Mol Carcinog,2019,58(5):749-759. [25] FUJIWARA N,NAKAGAWA H,ENOOKU K,et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity[J]. Gut,2018,67(8):1493-1504. [26] PONZIANI FR,BHOORI S,CASTELLI C,et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease[J]. Hepatology,2019,69(1):107-120. [27] YOSHIMOTO S,LOO TM,ATARASHI K,et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J]. Nature,2013,499(7456):97-101. [28] LOO TM,KAMACHI F,WATANABE Y,et al. Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity[J]. Cancer Discov,2017,7(5):522-538. [29] TANOUE T,MORITA S,PLICHTA DR,et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity[J]. Nature,2019,565(7741):600-605. -
本文二维码
计量
- 文章访问数: 920
- HTML全文浏览量: 29
- PDF下载量: 273
- 被引次数: 0
下载:
